ArticleClinical implications of maximal respiratory pressure determinations for individuals with duchenne muscular dystrophy☆,☆☆
References (33)
- et al.
Pulmonary function in Duchenne muscular dystrophy
Am J Med
(1974) - et al.
Pulmonary findings in progressive muscular dystrophy
Chest
(1972) - et al.
Pulmonary function in Duchenne muscular dystrophy related to stage of disease
Am J Med
(1974) Update and perspectives on noninvasive respiratory muscle aids: part 1-the inspiratory muscle aids
Chest
(1994)- et al.
Progressive muscular dystrophy and the myotonic disorders
Clinical features and classification of the muscular dystrophies
Br Med Bull
(1980)- et al.
Respiratory function in the muscular dystrophies
Muscle Nerve
(1981) Pronostique evolutif des dystrophies musculaires progressives liee au sexe
Neurol Med Canada
(1977)- et al.
Profiles of neuromuscular diseases: Duchenne muscular dystrophy
Am J Phys Med Rehabil
(1995) - et al.
Practical problems in the respiratory care of patients with muscular dystrophy
N Engl J Med
(1987)
Respiratory insufficiency in DMD
Cardiomyologica
Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies
Thorax
Respiratory failure in sleep and neuromuscular disease
Thorax
Analysis of lung volume restriction in patients with respiratory muscle weakness
Thorax
Maximal respiratory pressures: normal values and relationship to age and sex
Am Rev Respir Dis
Predicted normal values for maximal respiratory pressures in Caucasian adults and children
Thorax
Cited by (119)
Assessment of pulmonary function
2023, Pulmonary Assessment and Management of Patients with Pediatric Neuromuscular DiseasePulmonary and upper limbs function in children with early stage Duchenne muscular dystrophy compared to their healthy peers
2021, Brazilian Journal of Physical TherapyLongitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids
2018, Neuromuscular DisordersCitation Excerpt :Our study showed more relative impairment in PEFr%p early prior to age 10 and less of a steroid effect seen early for PEF%p in comparison to FVC%p. Steroid treatment produces cumulative differences in absolute values of PEFr, higher peak absolute values of PEFr obtained, and delay in the age at which absolute values begin to decline. In a placebo arm of a clinical trial, PEFr%p declined 8.9% in a largely non-ambulant cohort of steroid non-treated patients with mean age of 15.0 ± 2.5 [6,39]. When stratifying for baseline severity of pulmonary impairment measured by the FVC%p, 12-month and 24-month relative changes in PEFr%p are seen comparing GC users and non-users (Supplemental Tables S12-S13).
Systemic Complications of Muscular Dystrophies
2023, Current Clinical NeurologyBreathing in Duchenne muscular dystrophy: translation to therapy
2022, Journal of Physiology
- ☆
This work was performed at the Institut Duchenne de Boulogne, Poitiers, France.
- ☆☆
No commercial party having a direct or indirect interest in the subject matter of this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated.